Efficacy and tolerability of the modified Atkins diet in adults with pharmacoresistant XXXX : a prospective observational study.

@entity1 @entity410 @entity353 @entity1674 @entity302
PURPOSE: Evidence from the pediatric population exists for the efficacy of ketogenic diets in reducing @entity410 frequency in @entity1 with intractable @entity302 . Recent evidence suggests that a Modified Atkins Diet may be a beneficial form of cotherapy for adult @entity1 with pharmacoresistant @entity302 . METHODS: A prospective, open-label study was performed of adults > 18 years of age with pharmacoresistant @entity302 . Carbohydrates were restricted to 20 g/day. Fluids and calories from protein and fat were allowed ad libitum. KEY FINDINGS:     Eighteen @entity1 , ages 18-55 years, were initially enrolled. Using an intent-to-treat analysis, 12% had a >50% @entity410 reduction after 3 months; 28% after 6 months, and 21% after 12 months. Response at 3 months predicted response at 12 months in 79% of @entity1 . The mean decrease in weight was 10.9 kg and the mean decrease in body mass index (BMI) was 3.8, p = 0.01. Fourteen of 18 @entity1 (78%) completed 12 months of this diet. @entity1 experienced a decrease in @entity1674 from (mean) 1.22 to 0.9 mm (p = 0.02). SIGNIFICANCE: The Modified Atkins Diet demonstrates modest efficacy as cotherapy for some adults with pharmacoresistant @entity302 and may be also helpful for @entity353 . Financial and logistical barriers were significant factors for those who declined enrollment and for those who discontinued the study.
